title: Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial.
abstract: The current recommendations for active immunization after stem cell transplant (SCT) include 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7) from 3 months after transplant, followed by a 23-valent polysaccharide pneumococcal vaccine (PPV23). However, until now, the immune response to PPV23 after PCV7 has not been assessed after SCT. In the EBMT IDWP01 trial, 101 patients received 1 dose of PPV23 at 12 or 18 months, both after 3 doses of PCV7. The efficacy of PPV23 was assessed 1 month later and at 24 months after transplant by the pneumococcal serotype 1 and 5 antibody levels. Serotype 1 and 5 are not included in PCV7. Although the geometric mean concentrations were significantly higher 1 month after PPV23, for both antigens, the response rates (> or =0.15 microg/mL), in the range of 68-94%, were not different between groups independent of the assessment date. One PPV23 dose after 3 PCV7 doses, already known to increase the response to PCV7, also extends the serotype coverage given 12 or 18 months after transplant.
authors.affiliation: Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching Hospital, Hematology Department, and Paris 12 University, 94010 Créteil, France. carlcord@club-internet.fr
authors.forename: Catherine
authors.initials: C
authors.lastname: Cordonnier
authors.forename: Myriam
authors.initials: M
authors.lastname: Labopin
authors.forename: Virginie
authors.initials: V
authors.lastname: Chesnel
authors.forename: Patricia
authors.initials: P
authors.lastname: Ribaud
authors.forename: Rafael De La
authors.initials: Rde L
authors.lastname: Camara
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Martino
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Ullmann
authors.forename: Terttu
authors.initials: T
authors.lastname: Parkkali
authors.forename: Anna
authors.initials: A
authors.lastname: Locasciulli
authors.forename: Karima
authors.initials: K
authors.lastname: Yakouben
authors.forename: Karlis
authors.initials: K
authors.lastname: Pauksens
authors.forename: Eric
authors.initials: E
authors.lastname: Bonnet
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.forename: Dietger
authors.initials: D
authors.lastname: Niederwieser
authors.forename: Jane
authors.initials: J
authors.lastname: Apperley
authors.forename: Per
authors.initials: P
authors.lastname: Ljungman
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D002648:Child; D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000276:immunology*; D033581:Stem Cell Transplantation; D013296:Streptococcus pneumoniae / Q000276:immunology; D014180:Transplantation; D014184:Transplantation, Homologous; D014611:Vaccination / Q000379:methods*; D055815:Young Adult
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines